Table 2.
Univariate and multivariate analyses of factors associated with progression.
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (≥60 vs. <60 years) | 1.00 (0.99–1.01) | 0.40 | ||
| Sex (male vs. female) | 1.08 (0.89–1.34) | 0.51 | ||
| Etiology | 0.07 | |||
| HBV | 0.87 (0.67–1.11) | |||
| HCV | 0.69 (0.50–0.95) | |||
| Non-viral | 1 (ref) | |||
| Child-Pugh score | 1.05 (0.98–1.11) | 0.15 | ||
| AFP (≥200 vs. <200 ng/mL) | 1.57 (1.32–1.86) | <0.001 | 1.23 (1.02–1.48) | 0.03 |
| Tumor size (≥5 vs. <5 cm) | 2.45 (2.04–2.94) | <0.001 | 1.90 (1.53–2.36) | <0.001 |
| Tumor number (≥ multiple vs. single) | 1.73 (1.45–2.05) | <0.001 | 1.68 (1.41–2.02) | <0.001 |
| Vascular invasion | 2.48 (2.05–3.01) | <0.001 | 1.52 (1.20–1.93) | <0.001 |
| BCLC stage | <0.001 | - | 0.20 | |
| 0 | 1 (ref) | |||
| A | 1.34 (0.95–1.89) | |||
| B | 2.05 (1.41–2.98) | |||
| C | 3.04 (2.17–4.26) | |||
| D | 2.24 (1.33–3.78) | |||
| NLR | 1.12 (1.07–1.16) | <0.001 | 1.06 (1.02–1.11) | 0.007 |
| PLR | 1.00 (1.00–1.00) | <0.001 | - | 0.86 |
| SII | 1.00 (1.00–1.00) | <0.001 | - | 0.27 |
| APRI | 1.03 (1.02–1.05) | <0.001 | - | 0.06 |
| FIB-4 | 1.01 (1.00–1.03) | 0.03 | 1.02 (1.01–1.04) | 0.008 |
AFP, alpha-fetoprotein; APRI, aspartate aminotransferase-to-platelet ratio index; BCLC, Barcelona Clinic liver cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; CI, confidence interval; HR, hazard ratio; MELD-Na, model for end-stage liver disease-sodium; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index.